Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 13/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038090 | 1.00 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4HIF1AHSD17B10 | |
| SCHEMBL14999472 | 0.94 | SLC6A2 (0.45) | SLC6A2SLC6A3SLC6A4HIF1AHSD17B10 | |
| SCHEMBL26725297 | 0.89 | SLC6A2 (0.42) | SLC6A2SLC6A3SLC6A4HIF1AHSD17B10 | |
| SCHEMBL12965781 | 0.89 | SLC6A2 (0.42) | SLC6A2SLC6A3SLC6A4HIF1AHSD17B10 | |
| SCHEMBL21567213 | 0.83 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4HIF1AHSD17B10 | |
| SCHEMBL19622233 | 0.82 | SLC6A2 (0.43) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4829491 | 0.77 | — | — | |
| SCHEMBL6109208 | 0.77 | — | — | |
| SCHEMBL20960624 | 0.77 | SLC6A2 (0.45) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4651632 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404690-B2 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| EP-1592389-B1 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | SERONO LAB (CH) | 2009-04-22 | — | — | EP | disclosed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | disclosed |
| EP-1592389-A2 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004071390-A2 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | P2RX5, P2RX2, NPY5R | SLC6A2 4285/4885SLC6A3 4589/4885SLC6A4 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.